Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.33−0.25 (-1.84%)
Close on Nov 18, 2026Market cap $467.45MP/E –Yield –
Fennec Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Fennec Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $59.22M, up 77.8% year over year. For fiscal 2025 it was $44.64M, down 6.1% from the year before. The highest annual figure on record is $47.54M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.64M | -6.1% |
| FY2024 | Dec 31, 2024 | $47.54M | +123.7% |
| FY2023 | Dec 31, 2023 | $21.25M | +1284.5% |
| FY2022 | Dec 31, 2022 | $1.54M | +667.5% |
| FY2020 | Dec 31, 2020 | $200.00K | – |
| FY2019 | Dec 31, 2019 | $0 | – |
| FY2018 | Dec 31, 2018 | $0 | – |
| FY2017 | Dec 31, 2017 | $0 | – |
| FY2016 | Dec 31, 2016 | $0 | – |
| FY2015 | Dec 31, 2015 | $0 | – |
| FY2014 | Dec 31, 2014 | $0 | – |
| FY2013 | Dec 31, 2013 | $0 | – |
| FY2012 | Dec 31, 2012 | $0 | – |
| FY2011 | Dec 31, 2011 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $17.87M | +85.2% |
| Q1 FY2026 | Mar 31, 2026 | $15.11M | +72.6% |
| Q4 FY2025 | Dec 31, 2025 | $13.78M | +73.8% |
| Q3 FY2025 | Sep 30, 2025 | $12.46M | +78.7% |
| Q2 FY2025 | Jun 30, 2025 | $9.65M | +32.9% |
| Q1 FY2025 | Mar 31, 2025 | $8.75M | -65.5% |
| Q4 FY2024 | Dec 31, 2024 | $7.93M | -18.6% |
| Q3 FY2024 | Sep 30, 2024 | $6.97M | +7.0% |
| Q2 FY2024 | Jun 30, 2024 | $7.26M | +118.4% |
| Q1 FY2024 | Mar 31, 2024 | $25.38M | +1413.2% |
| Q4 FY2023 | Dec 31, 2023 | $9.74M | – |
| Q3 FY2023 | Sep 30, 2023 | $6.52M | +3157.5% |
| Q2 FY2023 | Jun 30, 2023 | $3.33M | – |
| Q1 FY2023 | Mar 31, 2023 | $1.68M | – |
| Q1 FY2021 | Mar 31, 2021 | $0 | – |
| Q4 FY2020 | Dec 31, 2020 | $200.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $0 | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | – |
| Q1 FY2018 | Mar 31, 2018 | $0 | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
| Q4 FY2016 | Dec 31, 2016 | $0 | – |
| Q3 FY2016 | Sep 30, 2016 | $0 | – |
See a number that looks wrong?